BioCentury | May 14, 2019
Company News

Management tracks: DBV, Beam, Aeon Biopharma

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said Deputy CEO and Principal Financial Officer David Schilansky will leave the company in August to pursue other opportunities. The allergy company is searching for a new CFO but will...
BioCentury | Apr 25, 2017
Distillery Techniques

Drug delivery; drug platforms

TECHNOLOGY: Polymers; cell therapy A functionalized biopolymer implantation platform containing CAR T cells and innate immunity-stimulating agents could help treat solid tumors. The platform consists of a polymerized alginate scaffold loaded with CAR T cells...
BioCentury | Apr 4, 2016
Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Yrs cash pre-cut Cash date 12-mo op loss ended 12/31 1/7/16 Sequenom Inc. (NASDAQ:SQNM) 20% to 390 $76.2 9.65 12/31/15 $7.9 Sequenom restructured to focus on women's health...
BioCentury | Feb 8, 2016
Company News

iCo ophthalmic, autoimmune, infectious news

iCo terminated all employees to preserve cash. In 2014, iCo reported that iCo-007 failed in a Phase II trial to treat diabetic macular edema (DME). The company said it has since conducted “an exhaustive search...
BioCentury | Dec 16, 2013
Strategy

Out in the cold

New excluded drugs lists devised by pharmacy benefits managers are raising the hurdle for reimbursement of drugs the PBMs' pharmacy and therapeutics committees consider to be clinically equivalent to cheaper drugs. Drugs that are not...
BioCentury | Sep 16, 2013
Company News

Bioniche cancer news

Bioniche reached a settlement with dissident shareholders, former Biovail Corp. CEO William Wells and former Biovail SVP Greg Gubitz. Under the settlement, Gubitz and Wells agreed to subscribe for an aggregate of C$250,000 ($240,245) of...
BioCentury | Sep 20, 2012
Tools & Techniques

Strategic synergy

...mechanism, the researchers looked at levels of tumor cell receptors and found that retinoic acid early inducible-1 ( Rae-1...
...by inducing retinoic acid early inducible-1 ( Rae-1 ) on tumor cells ( II ). The interaction of Rae-1...
BioCentury | Aug 6, 2012
Company News

Bioniche board of directors update

Bioniche Life Sciences Inc. (TSX:BNC; ASX:BNC), Belleville, Ontario Business: Cancer, Agbio/Environmental Appointed: James Rae, CEO of Viron Therapeutics Inc. , as chairman; he succeeds President and CEO Graeme McRae WIR Staff cancer...
BioCentury | Feb 20, 2012
Company News

Arrowhead management update

Arrowhead Research Corp. (NASDAQ:ARWR), Pasadena, Calif. Business: Drug delivery Hired: Brendan Rae as CBO, effective Nov. 1, 2011, formerly CBO of Vivaldi Biosciences Inc. WIR Staff...
BioCentury | Dec 8, 2011
Distillery Therapeutics

Indication: Dermatology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Dermatology Dermatitis Killer cell lectin-like receptor subfamily K member 1 (KLRK1; CD314; NKG2D); T cell receptor (TCR); RNA export 1 homolog (RAE1); CD3d molecule-d CD3-TCR complex...
Items per page:
1 - 10 of 15